The short answer: Mounjaro is not FDA-approved for obstructive sleep apnea (OSA). Its active ingredient, tirzepatide, is approved for moderate to severe OSA in adults with obesity, but only under the brand name Zepbound. In the trials behind that approval, tirzepatide cut breathing pauses by about 25 to 29 events per hour over 52 weeks. Those trials excluded people with type 2 diabetes, who are the people Mounjaro is approved for.
Is Mounjaro approved for sleep apnea?
No. The current Mounjaro label lists two uses, and both are for type 2 diabetes:
- To improve blood sugar control, with diet and exercise, in adults and children 10 years and older with type 2 diabetes.
- To reduce the risk of major cardiovascular events in adults with type 2 diabetes who are at high risk for them.
The label does not mention sleep apnea anywhere. The Zepbound label is different. It lists two uses, with a reduced-calorie diet and more physical activity: long-term weight reduction, and treatment of moderate to severe OSA in adults with obesity.
The FDA added the sleep apnea use on December 20, 2024. The agency called Zepbound the first drug treatment option for certain patients with obstructive sleep apnea. Both brands contain the same drug from the same company. The difference is the label, and the label defines which uses are on-label. Insurance plans often tie coverage to the labeled use. Our Mounjaro vs Zepbound comparison covers the brand split in full.
What did the tirzepatide sleep apnea trials find?
The evidence comes from SURMOUNT-OSA, published in the New England Journal of Medicine in 2024. It was two phase 3 trials run side by side. Trial 1 enrolled adults who were not using positive airway pressure (PAP) therapy. Trial 2 enrolled adults who were. Together they enrolled 469 adults with moderate to severe OSA and obesity. Each person received tirzepatide (the highest tolerated dose of 10 mg or 15 mg) or placebo once a week for 52 weeks.
The main measure was the apnea-hypopnea index (AHI). AHI counts how many times breathing stops or turns shallow in each hour of sleep. People started with severe disease on average: about 51.5 events per hour in trial 1 and 49.5 in trial 2. The average body mass index was about 39.
- Trial 1 (no PAP): AHI fell by 25.3 events per hour with tirzepatide and by 5.3 with placebo. The difference was 20.0 events per hour.
- Trial 2 (on PAP): AHI fell by 29.3 events per hour with tirzepatide and by 5.5 with placebo. The difference was 23.8 events per hour.
The Zepbound label adds more detail. AHI fell by about 51% and 59% from baseline in the two trials. Body weight fell by 17.7% and 19.6%, compared with 1.6% and 2.3% on placebo. About 42% and 50% of people on tirzepatide reached remission or mild OSA without daytime sleepiness, compared with about 16% and 14% on placebo. Blood pressure and an inflammation marker also improved.
Weight loss is the likely reason. The FDA states that the improvement in AHI "is likely related to body weight reduction." That fits how OSA works. The National Heart, Lung, and Blood Institute explains that people with obesity can have increased fat deposits in the neck that block the upper airway during sleep.
Does the evidence apply to people with type 2 diabetes?
This is the main gap for Mounjaro users. The Zepbound label states that patients with type 2 diabetes were excluded from both sleep apnea trials. The FDA describes the trial group as "469 adults without type 2 diabetes." So the group that Mounjaro is approved for was not tested for this outcome.
That does not mean the drug stops working on the airway in people with diabetes. The drug is the same, and the benefit appears to come from weight loss. It does mean two things are unknown. Nobody has measured the size of the AHI change in people with type 2 diabetes in a trial like this one. And the sleep apnea result was reached at 10 mg or 15 mg a week, which is the maintenance dose the Zepbound label gives for OSA. Mounjaro doses are set by blood sugar needs, so a person on a lower dose may not see the same weight loss or the same airway effect.
The trial group also had an average BMI near 39. If your BMI is lower, or your sleep apnea has a cause other than weight (large tonsils or jaw shape, for example), expect less benefit. For what weight change is typical on this brand, see our page on Mounjaro weight loss results.
Can Mounjaro replace CPAP?
Do not plan on it, and do not stop CPAP by yourself. The trials did not test that question. The Zepbound label says the OSA studies "did not evaluate the timing or appropriateness of PAP discontinuation" in people who were using PAP as directed.
The numbers explain why. An AHI of 15 or more counts as moderate OSA in the label, and 30 or more counts as severe. A person who starts near 50 and drops by 25 to 29 events per hour still has moderate OSA on average. Half or more of the people on tirzepatide did not reach remission or mild disease at one year.
The American Academy of Sleep Medicine tells clinicians that the goal of tirzepatide is not to replace traditional OSA treatments like CPAP. It describes the drug as "a tool, not a cure" and says CPAP should not be stopped without a proper reassessment. That reassessment is usually a repeat sleep study. The NHLBI still describes a PAP machine as the most common treatment for sleep apnea.
One more point from the same AASM article: stopping tirzepatide may undo the AHI improvement, because weight tends to return. Treat the benefit as something that lasts only while the weight stays off.
What should a Mounjaro user with sleep apnea do?
If you take Mounjaro for type 2 diabetes and also have OSA, these steps follow from the labels and the trial data:
- Keep using your current sleep apnea treatment. In the trials, the benefit was measured after 52 weeks. The trial authors note that OSA is associated with major cardiovascular complications.
- Tell your sleep clinician you take tirzepatide. Ask when a repeat sleep study makes sense after a large weight change.
- Do not add Zepbound to Mounjaro. The Zepbound label says use with other tirzepatide products or any GLP-1 receptor agonist is not recommended. They are the same drug.
- Ask before you switch brands. A switch to Zepbound for the sleep apnea indication is a decision for your prescriber. Zepbound is not labeled for blood sugar control, so the switch can change your coverage. Our guide to Mounjaro cost and insurance explains how plans treat each brand.
- Tell your surgical team before any procedure. The Mounjaro label warns of rare reports of pulmonary aspiration under general anesthesia or deep sedation in people taking GLP-1 drugs. People with OSA already get extra attention from anesthesia teams, so both facts belong in your pre-surgery history.
If you do not have diabetes and want tirzepatide for sleep apnea, Zepbound is the on-label brand. You need a sleep study that shows moderate to severe OSA, plus obesity. For how other drugs in this class compare on sleep apnea, see the GLP-1 drugs and sleep apnea overview on glp1.md.
The bottom line
Tirzepatide helps obstructive sleep apnea in adults with obesity. Two 52-week trials showed a drop of 20 to 24 events per hour beyond placebo. The FDA approved that use for Zepbound, not for Mounjaro, and the trials left out people with type 2 diabetes. A Mounjaro user who loses a lot of weight may breathe better at night, but that is an expected side benefit and not a labeled use. Keep your CPAP or oral device until a sleep clinician retests you.
Last updated: October 2026. This article is for informational purposes only and does not constitute medical advice. Talk with your prescriber and your sleep clinician before you change any sleep apnea treatment or diabetes medication.